2 Information about daridorexant
Marketing authorisation indication
2.1 Daridorexant (QUVIVIQ, Idorsia) is indicated for 'the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for daridorexant.